Generic Portfolio

About Sunshine Biopharma

Sunshine Biopharma's mission is to develop novel therapeutics for cancer and life-threatening diseases. Its key achievement is establishing a hybrid business model, combining revenue-generating generic drug sales in Canada with proprietary R&D focused on overcoming chemotherapy resistance and developing mRNA vaccines. The company's strategy is to use the cash flow from its commercial subsidiary to fund the advancement of its oncology pipeline, mitigating the financial volatility typical of early-stage biotechs. Its lead program, SBFM-PL4, represents a novel approach to a long-standing challenge in oncology.

About Dexcel Pharma USA

Dexcel Pharma USA is the U.S. subsidiary of Israel's largest private pharmaceutical company, Dexcel Pharma, established following the 2022 acquisition of Edenbridge Pharmaceuticals and a 2024 rebranding. The company commercializes a portfolio of generic, branded, and specialty products, with a strategic focus on complex conditions like multiple myeloma and Gaucher disease. It leverages its parent company's global R&D and manufacturing scale to provide affordable, high-quality medications, positioning itself as a trusted partner in the U.S. generic and specialty pharmaceutical market.

About Deva Holdings

Founded in 1958, Deva Holdings has grown from a domestic Turkish pharmaceutical player into an internationally recognized, publicly traded generics and API manufacturer. Its strategy is built on vertical integration, a strong R&D focus on bioequivalence, and geographic expansion into over 80 countries. Key achievements include establishing a significant export business, maintaining a diverse portfolio spanning multiple therapeutic areas, and operating a large-scale, end-to-end production infrastructure. The company's mission, 'For lives we add health to...', underscores its commercial focus on affordable, accessible medicine.

About Joincare Pharmaceutical Group Industry Co.

A Chinese integrated pharmaceutical company developing and manufacturing generic and innovative drugs across multiple therapeutic areas.

About Avalon Pharma (Middle East Pharmaceutical)

Avalon Pharma is a publicly traded Saudi pharmaceutical company with a mission to enhance healthcare accessibility through the development and manufacturing of quality medicines. Its strategy is deeply aligned with Saudi Arabia's Vision 2030, focusing on import substitution and building domestic pharmaceutical sovereignty. The company has established itself as a significant manufacturer with WHO-GMP compliant facilities and a growing portfolio. Its achievements include a strong market position on the Tadawul and a strategic role in the national healthcare ecosystem.

Therapeutic Areas